NCT04566887View on ClinicalTrials.gov

Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

September 30, 2023

Study Completion Date

April 30, 2032

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

Acalabrutinib

Administered as 100mg tablets.

DRUG

R-CHOP chemotherapy

R-CHOP chemotherapy

Trial Locations (5)

V5Z 4E6

RECRUITING

BC Cancer Agency, Vancouver

B3H 2Y9

RECRUITING

QEII Health Sciences Centre, Halifax

Unknown

RECRUITING

Princess Margaret Cancer Centre, Toronto

ACTIVE_NOT_RECRUITING

Sunnybrook Research Institute, Toronto

G1J 1Z4

RECRUITING

Centre Hospitalier Universitaire de Québec, Québec

All Listed Sponsors
lead

University Health Network, Toronto

OTHER